Drugs That Distort the Growth Hormone Stimulation Test

What Is a Growth Hormone Stimulation Test?

A GH stimulation test measures the pituitary gland's ability to release growth hormone after a pharmacologic provocation. Random GH levels are unreliable because GH is secreted in pulses, with most daytime values sitting near zero even in healthy adults. The test forces a peak, and that peak (or failure to reach one) forms the diagnostic basis.

The most validated protocols include the insulin tolerance test (ITT), the glucagon stimulation test (GST), the GHRH-arginine test, and the macimorelin test. Each agent triggers GH release through a different mechanism. The ITT induces hypoglycemia (blood glucose <40 mg/dL), which activates a counter-regulatory GH surge. Glucagon stimulates GH through a less well-understood pathway that involves secondary hypoglycemia and a direct hypothalamic signal. GHRH-arginine combines a releasing hormone with an inhibitor of somatostatin tone. Macimorelin, an oral ghrelin-receptor agonist approved by the FDA in December 2017, is the newest option and requires no IV access [1].

The 2011 Endocrine Society Clinical Practice Guideline defines adult GH deficiency as a peak GH below a test-specific cutoff, most commonly <5 mcg/L on the ITT or <3 mcg/L on GHRH-arginine [2]. A drug that blunts this peak, even slightly, can push a borderline-normal patient below the cutoff. That makes medication awareness a prerequisite to accurate interpretation.

Glucocorticoids: The Most Common Confounder

Supraphysiologic glucocorticoid exposure suppresses GH at every level of the hypothalamic-pituitary-somatotroph axis. Even replacement-dose hydrocortisone can matter. The effect is dose-dependent and cumulative.

Chronic prednisone use at doses above 7.5 mg/day suppresses pulsatile GH secretion by 40-70%, according to data from studies in patients on long-term steroid therapy for inflammatory disease (Giustina & Wehrenberg, 1995) [3]. A 2002 study published in the Journal of Clinical Endocrinology & Metabolism found that even hydrocortisone doses above 15 mg/day reduced IGF-1 levels and blunted GH peaks in adults with known hypopituitarism who were being tested for concomitant GH deficiency [4]. The problem: many patients referred for GH stim testing already take glucocorticoids for adrenal insufficiency. This creates a diagnostic trap where the very treatment for one pituitary deficit masks adequate function in another axis.

The clinical workaround is to minimize the glucocorticoid dose to the lowest safe replacement (typically hydrocortisone 10-15 mg/day in divided doses) for at least two weeks before testing. Complete withdrawal is rarely safe in patients with documented adrenal insufficiency, so clinicians must interpret borderline GH peaks with this confounder in mind. The 2011 Endocrine Society guideline states: "Glucocorticoid over-replacement should be corrected before GH testing is performed" [2].

Opioids and GH Suppression

Opioids suppress GH secretion through direct action on mu-opioid receptors in the hypothalamus, increasing somatostatin tone and reducing GHRH output. This is not a subtle effect. A study of chronic opioid users found that peak GH responses to stimulation were reduced by approximately 50% compared to matched controls [5].

Short-acting opioids like hydrocodone and oxycodone clear within 24-48 hours, but hypothalamic-pituitary suppression can persist for 1-2 weeks after cessation. Long-acting formulations (methadone, extended-release morphine, buprenorphine) require longer washout periods. Buprenorphine's partial agonism may cause less GH suppression than full agonists, but data remain limited [6].

The practical challenge is real. Patients referred for GH stim testing often have chronic pain conditions managed with opioids. Abrupt discontinuation introduces withdrawal risk. A planned taper or temporary substitution with non-opioid analgesics, coordinated with the prescribing pain specialist, should begin at least two weeks before the test when medically safe. If opioid withdrawal is not feasible, the interpreting endocrinologist should document the confounder and consider retesting if results are equivocal.

Sex Steroids, Estrogen, and the Priming Problem

Estrogen's effect on GH testing is route-dependent. Oral estrogen undergoes first-pass hepatic metabolism, which suppresses hepatic IGF-1 production without changing actual GH secretion. This means IGF-1, the screening test that often triggers the stim test referral, can be misleadingly low in women taking oral contraceptives or oral hormone therapy. Transdermal estrogen bypasses the liver and does not cause this artifact (Ho et al., 2006) [7].

The distinction matters clinically. A premenopausal woman on combined oral contraceptives may have an IGF-1 of 80 ng/mL (below the age-adjusted reference range), prompting unnecessary GH stimulation testing. Switching to transdermal estrogen or discontinuing oral estrogen for 4-6 weeks before measuring IGF-1 can prevent this cascade.

In pediatric testing, estrogen priming before GH stimulation has a different and equally significant role. Prepubertal children, particularly boys in early puberty (Tanner stage I-II), have physiologically low sex steroid levels that blunt GH responses. Without estrogen or testosterone priming, up to 60% of normally-growing prepubertal children can fail a GH stim test [8]. The Pediatric Endocrine Society recommends sex-steroid priming (ethinyl estradiol 40 mcg orally for 2 days in girls; testosterone 50-100 mg IM 3-7 days before in boys) for prepubertal children undergoing provocative testing [9]. Without it, the false-positive rate for GH deficiency is unacceptably high.

Testosterone replacement therapy in adult men increases GH secretion modestly through aromatization to estradiol at the hypothalamic level. A man on testosterone cypionate 200 mg/week may have a slightly higher GH peak than his untreated baseline, which could theoretically mask mild GH deficiency. This effect is small enough that testosterone is not routinely held before GH testing in adults, though it should be documented.

Obesity and Adiposity: The Non-Drug Drug

Body fat is not a medication, but it functions as one during GH testing. Obesity is the single most potent suppressor of stimulated GH peaks outside of organic pituitary disease. A 2008 analysis in the Journal of Clinical Endocrinology & Metabolism found that BMI above 30 kg/m² reduced peak GH on GHRH-arginine testing by more than 50%, with a mean peak of 8.2 mcg/L in obese subjects versus 19.3 mcg/L in lean controls [10].

This creates a diagnostic gray zone. The standard GHRH-arginine cutoff of 11.5 mcg/L misclassifies a significant proportion of obese but GH-sufficient individuals as deficient. BMI-adjusted cutoffs have been proposed: <11.5 mcg/L for BMI <25, <8.0 mcg/L for BMI 25-30, and <4.2 mcg/L for BMI above 30. The macimorelin test uses a single cutoff of 2.8 mcg/L that appears less susceptible to BMI confounding, with 92% concordance with the ITT across weight categories [11].

GLP-1 receptor agonists like semaglutide deserve attention in this context. These drugs produce significant weight loss (14.9% mean body weight reduction at 68 weeks in STEP-1, N=1,961), and that weight loss can unmask a previously suppressed GH axis [12]. A patient who failed a GH stim test at BMI 38 might pass after losing 20 kg on semaglutide. Whether to retest after major weight loss is a clinical judgment, but the possibility of a false-positive initial result should be considered.

As Dr. Kevin Yuen of the Barrow Neurological Institute has noted regarding obesity's effect on GH diagnostics: "The BMI-dependent reduction in GH peak creates a significant risk of overdiagnosis of GH deficiency in obese patients, and providers should use BMI-stratified cutoffs or choose test agents less affected by adiposity" [13].

Psychotropic Medications and Dopaminergic Agents

Multiple psychiatric medications interact with GH testing through their effects on hypothalamic neurotransmitter systems. The interactions vary by drug class and are sometimes bidirectional.

Atypical antipsychotics (risperidone, olanzapine, quetiapine) increase prolactin and may suppress GH through enhanced somatostatin tone. Risperidone in particular raises prolactin substantially, and hyperprolactinemia itself can blunt GH responses (Toogood et al., 1998) [14]. Holding antipsychotics before testing is often not clinically safe, so the confounder must be acknowledged in the interpretation.

SSRIs have a more complex relationship with GH. Acute SSRI administration can stimulate GH release through serotonergic pathways, but chronic use (over 4 weeks) appears to normalize or slightly suppress GH dynamics. The magnitude of this effect is generally modest, and SSRIs are not routinely held before GH stim testing. The clinician should document their use but need not delay testing solely because of SSRI therapy.

Dopamine agonists (cabergoline, bromocriptine) can paradoxically suppress GH in patients with acromegaly but have variable effects in GH-deficient patients. In normal physiology, dopamine stimulates GH release. In pituitary adenomas that co-secrete GH and prolactin, dopamine agonists may suppress GH secretion from the tumor. These should be held for at least 4 weeks before testing if the clinical question is whether GH deficiency exists.

Amphetamines and methylphenidate stimulate GH release acutely through adrenergic and dopaminergic mechanisms. A child taking methylphenidate who undergoes a GH stim test on the same day may have a falsely elevated peak, potentially masking true GH deficiency. The Endocrine Society recommends holding stimulant medications for at least 48-72 hours before provocative GH testing in children [9].

Anti-Hyperglycemic Agents and Metabolic Drugs

The insulin tolerance test relies on inducing hypoglycemia to provoke a GH response. Any drug that prevents blood glucose from falling below 40 mg/dL will invalidate this specific test.

Metformin alone rarely prevents the hypoglycemia needed for the ITT, but sulfonylureas can cause unpredictable glucose swings that complicate test interpretation. SGLT2 inhibitors (empagliflozin, dapagliflozin) do not typically prevent hypoglycemia but may alter the counter-regulatory response at a subclinical level.

The more clinically relevant scenario involves patients on insulin therapy (type 1 or type 2 diabetes) undergoing ITT. These patients have altered counter-regulatory hormone responses from recurrent hypoglycemia. A patient with hypoglycemia unawareness may fail to mount a normal cortisol and GH surge during the ITT despite having an intact pituitary. This is a physiologic confounder rather than a drug interaction in the traditional sense, but it argues for choosing an alternative provocative agent (glucagon or macimorelin) in insulin-treated diabetic patients.

Somatostatin analogs (octreotide, lanreotide), used primarily in acromegaly and neuroendocrine tumors, directly suppress GH secretion and must be held before GH deficiency testing. Octreotide LAR should be discontinued for at least 3 months before provocative testing, as depot formulations release drug slowly from the injection site (Melmed et al., 2018) [15].

How to Prepare: A Pre-Test Medication Review

The Endocrine Society's 2011 guideline recommends a thorough medication review before any provocative GH test. The guideline states: "Clinicians should assess for medications and conditions that may affect GH secretion and should correct reversible factors before testing" [2]. A structured approach reduces false results.

The medication hold timeline varies by drug class. Oral estrogens should be switched to transdermal or discontinued 4-6 weeks before IGF-1 measurement. Opioids require a 1-2 week washout when safe. Glucocorticoids should be reduced to the minimum safe replacement dose for at least 2 weeks. Stimulant medications (amphetamines, methylphenidate) need a 48-72 hour hold. Somatostatin analogs require a 3-month washout for depot formulations and 48 hours for subcutaneous octreotide. Dopamine agonists should be held for 4 weeks.

Some medications cannot be safely discontinued. Antipsychotics, anticonvulsants, and essential cardiovascular drugs typically must remain in place. In these cases, the interpreting physician should document the confounder, apply appropriately conservative diagnostic cutoffs, and consider retesting if clinical suspicion remains high despite a borderline result.

Recording the patient's current BMI, concurrent medications, and last dose timing in the test requisition gives the interpreting endocrinologist the data needed to contextualize the GH peak. A peak GH of 4.5 mcg/L means something very different in a lean 25-year-old on no medications than in a 55-year-old with BMI 34 on prednisone 10 mg and oxycodone 20 mg daily.

Choosing the Right Test Agent

Not all provocative agents are equally susceptible to drug interference. Test selection itself is a strategy for minimizing confounders.

The ITT remains the reference standard per the Endocrine Society guideline but is contraindicated in patients with seizure disorders, ischemic heart disease, and age over 65 [2]. It is also unreliable in patients with impaired counter-regulatory responses from diabetes.

The GHRH-arginine test is highly susceptible to BMI confounding and requires BMI-adjusted cutoffs. GHRH (tesamorelin in the US) acts at the hypothalamic level, meaning patients with hypothalamic disease may show a false-normal response because the pituitary itself is intact.

The macimorelin test, validated in a key trial of 157 patients against the ITT, showed 87% sensitivity and 96% specificity for adult GHD at a cutoff of 2.8 mcg/L [11]. Its oral administration, fixed cutoff, and reduced BMI sensitivity make it an attractive option when multiple drug confounders are present. Macimorelin should not be co-administered with drugs that are strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin), as these can increase macimorelin exposure and potentially produce false-normal GH peaks.

The glucagon stimulation test is preferred in patients with seizure risk or cardiovascular contraindications to the ITT. Peak GH cutoffs for glucagon vary between 1 and 3 mcg/L depending on the assay and reference population, and BMI correction is recommended [16].